Population
Patients with atrial fibrillation
Design
Editorial
Authors
Loading...
This letter emphasizes that calculations of the net clinical benefit of warfarin in atrial fibrillation should incorporate its potential to reduce myocardial infarction and death, as well as the critical role of time in therapeutic range (TTR).
This letter emphasizes that calculations of the net clinical benefit of warfarin in atrial fibrillation should incorporate its potential to reduce myocardial infarction and death, as well as the critical role of time in therapeutic range (TTR).
Henry I. Bussey (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: